 | Up a level |
Everts-Graber, J; Reichenbach, Stephan; Gahl, Brigitta; Ziswiler, H R; Studer, U; Lehmann, T (2021). Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone, 144, p. 115830. Elsevier 10.1016/j.bone.2020.115830
Everts-Graber, J; Reichenbach, S.; Ziswiler, H R; Studer, U; Lehmann, T (2020). A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Journal of bone and mineral research, 35(7), pp. 1207-1215. Wiley-Blackwell 10.1002/jbmr.3962
Halter, J; Schüpbach, W M M; Casali, C; Elhasid, R; Fay, K; Hammans, S; Illa, I; Kappeler, L; Krähenbühl, S; Lehmann, T; Mandel, H; Marti, R; Mattle, H; Orchard, K; Savage, D; Sue, C M; Valcarcel, D; Gratwohl, A; Hirano, M (2010). Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone marrow transplantation, 46(3), pp. 330-337. London: Nature Publishing Group 10.1038/bmt.2010.100
